GLP-1 drugs protect against new or worsening addictions, large study shows

Core Insights - GLP-1 drugs, including Ozempic and Mounjaro, show potential in preventing new substance use disorders and alleviating existing addictions among patients with type 2 diabetes, as evidenced by a large study involving U.S. military veterans [1][1][1] Group 1: Study Findings - The study revealed that GLP-1 drug users had a 14% lower likelihood of developing new substance use disorders compared to those on SGLT-2 inhibitors over three years [1][1] - Specific reductions in substance use disorders were noted: 18% for alcohol, 14% for cannabis, 20% for cocaine, 26% for nicotine, and 25% for opioids [1][1] - Among patients with existing substance use disorders, GLP-1 users experienced a 31% reduction in emergency department visits, 26% fewer hospital admissions, 50% fewer related deaths, 39% fewer drug overdoses, and 25% fewer instances of suicidal ideation or attempts [1][1] Group 2: Biological Mechanism - The study suggests a common biological pathway for addiction that GLP-1 drugs may target, acting on GLP-1 receptors in the mesolimbic system, which is involved in motivation and reward signaling [1][1] - This mechanism may help suppress cravings for various addictive substances, indicating a broader application of GLP-1 drugs in addiction treatment [1][1] Group 3: Future Research and Implications - Further research is needed to determine the long-term effects of GLP-1 drugs on addiction and whether the benefits persist over time [1][1] - The VA plans to conduct a clinical trial testing semaglutide in veterans with alcohol use disorder, highlighting the potential for GLP-1 drugs in addiction management [1][1] - The findings suggest that GLP-1 receptor agonists may be considered in treatment plans for patients with type 2 diabetes who are also at risk for substance use disorders [1][1]